We believe that this could lead to novel vaccination strategies in which a pan-DR epitope such as PADRE could be tethered to validated CD8+ T cell targets as synthetic hybrid peptides if a suitable tumor-specific helper epitope is unavailable (51). Here, CD8A is linked to neoplasm.